Trial Profile
A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere) and Trastuzumab (Herceptin) With Docetaxel (Taxotere), Carboplatin and Trastuzumab (Herceptin) as First Line Chemotherapy for Patients With Advanced Breast Cancer Containing the HER2 Gene Amplification.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Carboplatin; Docetaxel
- Indications Advanced breast cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 22 Dec 2009 Planned end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 08 May 2009 Additional lead trial centres identified as reported by Australian New Zealand Clinical Trials Registry.
- 08 May 2009 New source identified and integrated Australian New Zealand Clinical Trials Registry.